Myomo Welcomes 13 New Center of Excellence Locations
March 12 2018 - 7:00AM
Business Wire
Expands Availability of MyoPro® Powered Arm
Brace to 46 Locations Nationwide
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
commercial stage medical robotics company, today announced the
addition of three new orthotics and prosthetics (O&P) practices
and 13 new locations to its MyoPro Center of Excellence (CoE)
program, which recognizes top O&P practices that support the
MyoPro line of powered orthoses. The addition of the practices
brings the total number of CoE locations across the United States
to 46.
MyoPro Centers of Excellence have met Myomo’s exacting standards
for providing quality patient care and have proven their expertise
in evaluating candidates and fitting them with the MyoPro powered
upper limb orthotic. MyoPro is currently the only lightweight
wearable device that can help restore function in the paralyzed or
weakened arms and hands of individuals who have suffered a stroke,
brachial plexus injury (BPI) or other neuromuscular disability.
The new CoE practices and locations announced today include:
- Wright & Filippis, Michigan’s
largest O&P practice; locations supporting MyoPro in Kalamazoo,
Battle Creek, Flint, Lansing, Livonia, Ann Arbor, Madison Heights,
Detroit, Saginaw and Clinton Township
- East Coast Orthotic & Prosthetic
(ECOP); locations in Deer Park, New York and Buffalo, New York
- Bionics Orthotics & Prosthetics;
location in San Diego, California
Myomo CoEs participate in joint marketing efforts and receive
training and patient support from Myomo. They also partner with
physicians and therapists at leading U.S. rehabilitation hospitals,
who recommend and prescribe MyoPro as well as train new MyoPro
users.
“The expanding MyoPro Center of Excellence program affords
patients the opportunity to receive quality care closer to their
homes,” said Paul R. Gudonis, Chairman and CEO of Myomo. “Our
goal is to make MyoPro readily accessible to as much of the U.S.
population as possible within this year.”
About MyomoMyomo, Inc. is a commercial stage medical
robotics company that offers expanded mobility for those suffering
from neurological disorders and upper limb paralysis. Myomo
develops and markets the MyoPro product line. MyoPro is a powered
upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering
from CVA stroke, brachial plexus injury, traumatic brain or spinal
cord injury, ALS or other neuromuscular disease or injury. It is
currently the only marketed device that, sensing a patient’s own
EMG signals through non-invasive sensors on the arm, can restore an
individual’s ability to perform activities of daily living,
including feeding themselves, carrying objects and doing household
tasks. Many are able to return to work, live independently and
reduce their cost of care. Myomo is headquartered in Cambridge,
Massachusetts, with sales and clinical professionals across the
U.S. For more information, please visit www.myomo.com.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations, the addition of the new CoE locations and the
commercialization of our MyoPro product, which are subject to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are only predictions
and may differ materially from actual results due to a variety of
factors. Our actual results could differ materially from those
anticipated in these forward looking statements for many reasons,
including, without limitation, risks related to regulatory approval
and market acceptance of our products, and the other risk factors
contained in our filings made with the Securities and Exchange
Commission. More information about factors that potentially could
affect Myomo's financial results is included in Myomo's filings
with the Securities and Exchange Commission. The Company cautions
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company
disclaims any obligation subsequently to revise any forward-looking
statements to reflect events or circumstances after the date of
such statements or to reflect the occurrence of anticipated or
unanticipated events.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180312005174/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2024 to May 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From May 2023 to May 2024